stoxline Quote Chart Rank Option Currency Glossary
ProMIS Neurosciences, Inc. (PMN)
2.342  -0.048 (-2.01%)    04-12 16:00
Open: 2.3
High: 2.4499
Volume: 3,491
Pre. Close: 2.39
Low: 2.3
Market Cap: 44(M)
Technical analysis
2024-04-12 4:51:33 PM
Short term     
Mid term     
Targets 6-month :  3.04 1-year :  3.56
Resists First :  2.6 Second :  3.04
Pivot price 2.13
Supports First :  2.07 Second :  1.75
MAs MA(5) :  2.39 MA(20) :  2.08
MA(100) :  1.77 MA(250) :  2.74
MACD MACD :  0.1 Signal :  0
%K %D K(14,3) :  71.3 D(3) :  80.3
RSI RSI(14): 57.9
52-week High :  8.94 Low :  0.94
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PMN ] has closed below upper band by 28.2%. Bollinger Bands are 50.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.46 - 2.47 2.47 - 2.48
Low: 2.27 - 2.28 2.28 - 2.3
Close: 2.32 - 2.35 2.35 - 2.37
Company Description

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Headline News

Tue, 09 Apr 2024
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic ... - GlobeNewswire

Sat, 06 Apr 2024
FY2024 EPS Estimates for ProMIS Neurosciences, Inc. (NASDAQ:PMN) Decreased by Leede Jones Gab - Defense World

Thu, 04 Apr 2024
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April - Yahoo Finance

Mon, 01 Apr 2024
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights - GlobeNewswire

Thu, 22 Feb 2024
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference - Yahoo Finance

Fri, 12 Jan 2024
PMN Stock Quote Price and Forecast - CNN

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 19 (M)
Shares Float 11 (M)
Held by Insiders 24.4 (%)
Held by Institutions 17.7 (%)
Shares Short 24 (K)
Shares Short P.Month 18 (K)
Stock Financials
EPS -1.89
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.37
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -114 %
Return on Equity (ttm) -451.6 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.13
Qtrly Earnings Growth 0 %
Operating Cash Flow -12 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio -1.24
PEG Ratio 0
Price to Book value 6.32
Price to Sales 0
Price to Cash Flow -3.81
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android